Literature DB >> 9627331

PET imaging of prostate cancer using carbon-11-choline.

T Hara1, N Kosaka, H Kishi.   

Abstract

UNLABELLED: Prostate cancer is difficult to visualize using current techniques. Recently, 31P magnetic resonance spectroscopy has revealed that the tumor, in general, is characterized by an increased uptake of choline into the cell to meet increased synthesis of phosphatidylcholine, an important cell membrane phospholipid. We succeeded in using 11C-choline to visualize prostate cancer and its local metastasis in PET.
METHODS: PET was performed on 10 prostate cancer patients from the level of pelvis to the lower abdomen. After transmission scanning, 370 MBq 11C-choline were injected intravenously. The emission scan was performed 5-15 min postinjection. Finally, PET images were displayed so that each pixel was painted by a specified color representing the degree of the standardized uptake value (SUV). The 11C-choline image was compared with the 18F-fluorodeoxyglucose (FDG) image obtained from the same patient.
RESULTS: Imaging of prostate cancer and its local metastasis was difficult when 18F-FDG was used because, within the pelvis, the areas of high uptake were concealed by the overwhelmingly abundant radioactivity in urine (in ureters and bladder). By contrast, it was easy when 11C-choline was used because the urinary activity was negligible and tumor uptake was marked. The radioactivity concentration of 11C-choline in prostate cancer and metastatic sites was at an SUV of more than three in most cases. The SUV of 18F-FDG was considerably lower than that of 11C-choline.
CONCLUSION: Prostate cancer and its local metastasis were visualized clearly in PET using 11C-choline.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627331

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  134 in total

Review 1.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Is 11C-choline the most appropriate tracer for prostate cancer? For.

Authors:  Ferruccio Fazio; Maria Picchio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-02       Impact factor: 9.236

3.  Is 11C-choline the most appropriate tracer for prostate cancer? Against.

Authors:  Klaus Zöphel; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-02       Impact factor: 9.236

4.  PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Authors:  Giampiero Giovacchini; Maria Picchio; Vincenzo Scattoni; Rita Garcia Parra; Alberto Briganti; Luigi Gianolli; Francesco Montorsi; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

Review 5.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

6.  Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study.

Authors:  Fatma Al-Saeedi
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

Review 7.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

8.  Usefulness of Choline-PET for the detection of residual hemangiopericytoma in the skull base: comparison with FDG-PET.

Authors:  Shin Ito; Junkichi Yokoyama; Hitoshi Yoshimoto; Masaki Yazawa; Kubota Kazuo; Makoto Hanaguri; Shinichi Ohba; Mitsuhisa Fujimaki; Katsuhisa Ikeda
Journal:  Head Face Med       Date:  2012-02-07       Impact factor: 2.151

9.  [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography.

Authors:  Julius Leyton; Graham Smith; Yongjun Zhao; Meg Perumal; Quang-De Nguyen; Edward Robins; Erik Arstad; Eric O Aboagye
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

Review 10.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.